The results from the ANSWER study have proven that intravenous treatment with human albumin improves the course of disease, with a lower incidence of almost all common complications and longer survival of patients with decompensated liver cirrhosis and pronounced ascites [45]. This evidence concerns the gene ALB and cirrhosis of liver.